Immix Biopharma Inc (IMMX) Hedge Fund & Institutional Holdings (Q2 2026)

IMMX ranks #4376 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

IMMX is a top-conviction position for Saturn V Capital Management LP — at 6.9% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in IMMX belongs to Jupiter Topco LLC, but the position matters far more to Saturn V Capital Management LP, who has 6.9% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Saturn V Capital Management LP has added to its IMMX position for two straight quarters, increasing it by $32.3M to reach $48.0M today.

Blue Owl Capital Holdings LP has trimmed its IMMX position for two straight quarters, cutting it by $646.9K while still holding $4.5M.

IMMX is down 2.6% today, but institutions show net buying of $253.7M this quarter — a divergence between today's price move and the underlying institutional flow.

IMMX reported a net loss of $29.4M in its latest fiscal year.

• Not yet profitable — net loss of $29.4M in the latest fiscal year
• Net income declined year over year, from -$21.6M to -$29.4M
• Operating cash flow was negative, using $23.9M in cash
• Current ratio of 10.01x — enough short-term assets to cover short-term liabilities
• Liabilities run 2083.41x equity — a highly leveraged balance sheet worth noting